Total Funding
40
77
Total FundingVenture - Series Unknown raised
Growth Score
1 pts
Heat Score
2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
33548
Angarus Therapeutics enhances immuno-oncology therapies intended to respond to the urgent needs of cancer treatment.
- Nigel Ray: President & CEO
- Lingyin Li: Scientific Co-Founder
About the Company
Angarus Therapeutics develops immuno-oncology therapies intended to respond to the urgent needs of cancer treatment.
The therapy serves as checkpoint blockers on the innate immunity STING pathway, with preclinical data demonstrating that a combination of checkpoint blockers, both innate and adaptive, leads to long term survival, enabling patients
with a wide range of cancer treatments.
Chih-Ping Liu established the company in Sunnyvale, California in 2018.
Women Founded
